| Issue Type | Login |
|---|---|
| Country | United States |
| Industry | Login |
| Region | Login |
| Maturity Date | 2043-08-15 |
| Par Value | 2000 |
| Callable | Login |
| Next Call Date | Login |
| Call Type | Login |
| Call Price (%) | Login |
| Series | Login |
| Class | Login |
| Maturity Structure | Login |
| Amount Outstanding (mil) | 4.06 |
| Coupon | 5.25 |
|---|---|
| Coupon Type | Login |
| Coupon Frequency | Login |
| First Coupon Date | Login |
| Last Coupon Date | Login |
| Sinking Fund | Login |
|---|---|
| Security | Login |
| Subordination | Login |
| Debt Type | Login |
| Issue Date | Login |
|---|---|
| Dated Date | Login |
| Issue Size (mil) | 400 |
| Min. Piece | Login |
| Min. Increment | Login |
This Celgene Corp. corporate note has a 5.25% fixed rate coupon paid on a Login basis. It was issued on MAR 12, 2000 with an issue size of 400.00 million USD and matures on August 15, 2043 with a last coupon date of FEB 28, 2020. |
Celgene Corp., founded in 1986 and headquartered in Summit, New Jersey, is a biopharmaceutical company dedicated to developing innovative therapies for cancer and inflammatory disorders. The company's prominent products include Revlimid, a treatment for multiple myeloma, and Pomalyst, used for relapsed or refractory multiple myeloma, which have positioned Celgene as a leader in the biotechnology sector.